3-Amido-4-anilinocinnolines as a novel class of CSF-1R inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 5, 2011, Pages 1382-1384

  Scott, David A ^a   Dakin, Les A ^a   Del Valle, David J ^a   Bruce Diebold, R ^a   Drew, Lisa ^a   Gero, Thomas W ^a   Ogoe, Claude A ^a   Omer, Charles A ^a   Repik, Galina ^a   Thakur, Kumar ^a   Ye, Qing ^a   Zheng, Xiaolan ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Cinnoline; CSF 1R; Kinase inhibitor

Indexed keywords

3 AMIDO 4 ANILINOCINNOLIN; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR 1 RECEPTOR INHIBITOR; COLONY STIMULATING FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

AMIDES; ANILINE COMPOUNDS; ANIMALS; DOGS; HETEROCYCLIC COMPOUNDS, 2-RING; MICE; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; RATS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79951722750     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.01.033     Document Type: Article

References (15)

1. S. Patel, and M.R. Player Curr. Top. Med. Chem. 9 2009 599
2. D.A. Scott, C.L. Balliet, D.J. Cook, A.M. Davies, T.W. Gero, C.A. Omer, S. Poondru, M.-E. Theoclitou, B. Tyurin, and M.J. Zinda Bioorg. Med. Chem. Lett. 19 2009 697
3. D.A. Scott, K.J. Bell, C.T. Campbell, D.J. Cook, L.A. Dakin, D.J. Del Valle, L. Drew, T.W. Gero, M.M. Hattersley, C.A. Omer, B. Tyurin, and X. Zheng Bioorg. Med. Chem. Lett. 19 2009 701
4. Drew, L.; Bell, K.; Dakin, L.; Hattersley, M.; Lawson, D.; Repik, G.; Scott, D.; Shen, M.; Omer, C. Abstract of Papers, 100th Annual Meeting of the American Association for Cancer Research, Denver, CO, AACR: Philadelphia, PA, 2009; Abstract 259.
5. L.F. Hennequin, A.P. Thomas, C. Johnstone, E.S.E. Stokes, P.A. Ple, J.-J.M. Lohmann, D.J. Ogilvie, M. Dukes, S.R. Wedge, J.O. Curwen, J. Kendrew, and C. Lambert-van der Brempt J. Med. Chem. 42 1999 5369
6. G.W. Rewcastle, W.A. Denny, A.J. Bridges, H. Zhou, D.R. Cody, A. McMichael, and D.W. Fry J. Med. Chem. 38 1995 3482
7. Bearss, D. J.; Vankayalapati, H.; Grand, C. L. WO 06124996 A2 20061123; Chem. Abstr. 145, 505465.
8. C. Lunniss, C. Eldred, N. Aston, A. Craven, K. Gohil, B. Judkins, S. Keeling, L. Ranshaw, E. Robinson, T. Shipley, and N. Trivedi Bioorg. Med. Chem. Lett. 20 2010 137
9. H.A. Dowlatshahi Synth. Commun. 15 1985 1095
10. D.A. Scott, B.M. Aquila, G.A. Bebernitz, D.J. Cook, L.A. Dakin, T.L. Deegan, M.M. Hattersley, S. Ioannidis, P.D. Lyne, C.A. Omer, M. Ye, and X. Zheng Bioorg. Med. Chem. Lett. 18 2008 4794
11. T. Sugasawa, T. Toyoda, M. Adachi, and K. Sasakura J. Am. Chem. Soc. 100 1978 4842
12. Dahmen, J.; Hemmerling, M.; Klingstedt, T.; Sjoe, P. WO 04016615 A1 20040226; Chem. Abstr. 140, 217650.
13. hERG activity was assessed using the Ionworks assay.
14. KinaseProfiler Department, Millipore UK Limited, Gemini Crescent, Dundee Technology Park, Dundee DD2 1SW, UK.
15. Enzyme assay conditions are described in: Dakin, L.; Ogoe, C. A.; Scott, D.; Zheng, X. WO 2008090353 A1 20080731; Chem. Abstr. 149, 224267.